A detailed history of Tower Research Capital LLC (Trc) transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 13,852 shares of TSHA stock, worth $34,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,852
Previous 13,037 6.25%
Holding current value
$34,214
Previous $29,000 6.9%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.01 - $2.46 $1,638 - $2,004
815 Added 6.25%
13,852 $27,000
Q2 2024

Aug 13, 2024

SELL
$2.04 - $4.17 $22,627 - $46,253
-11,092 Reduced 45.97%
13,037 $29,000
Q1 2024

May 15, 2024

BUY
$1.43 - $3.25 $30,398 - $69,088
21,258 Added 740.44%
24,129 $69,000
Q4 2023

Feb 13, 2024

BUY
$1.33 - $2.88 $3,818 - $8,268
2,871 New
2,871 $5,000
Q2 2023

Aug 14, 2023

BUY
$0.59 - $0.87 $4,236 - $6,246
7,180 Added 98.97%
14,435 $9,000
Q1 2023

May 09, 2023

SELL
$0.65 - $2.3 $2,445 - $8,654
-3,763 Reduced 34.15%
7,255 $6,000
Q4 2022

Feb 10, 2023

BUY
$1.39 - $2.98 $2,300 - $4,931
1,655 Added 17.68%
11,018 $25,000
Q3 2022

Nov 10, 2022

BUY
$1.76 - $4.94 $10,743 - $30,153
6,104 Added 187.3%
9,363 $18,000
Q2 2022

Aug 15, 2022

BUY
$2.47 - $6.77 $4,097 - $11,231
1,659 Added 103.69%
3,259 $12,000
Q1 2022

May 12, 2022

BUY
$5.22 - $11.86 $2,192 - $4,981
420 Added 35.59%
1,600 $10,000
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $4,457 - $7,488
390 Added 49.37%
1,180 $14,000
Q3 2021

Nov 15, 2021

SELL
$15.82 - $21.57 $2,942 - $4,012
-186 Reduced 19.06%
790 $15,000
Q2 2021

Aug 16, 2021

BUY
$19.29 - $26.38 $6,751 - $9,233
350 Added 55.91%
976 $21,000
Q1 2021

May 17, 2021

BUY
$20.3 - $31.75 $6,759 - $10,572
333 Added 113.65%
626 $13,000
Q4 2020

Feb 16, 2021

BUY
$19.14 - $28.13 $5,608 - $8,242
293 New
293 $8,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $119M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.